Evaluating the benefits of metformin in metastatic prostate cancer: (ADMET) trial
Researchers are leading a world-first study using a common diabetes treatment Metformin to help men undergoing Androgen Deprivation Therapy (ADT).
| Head Researcher | Prof Colleen Nelson |
|---|---|
| Team Members |
Dr Handoo Rhee |
| Body Part | Prostate |
| Equipment Used | |
| Process Used | Testing a drug used to treat patients with diabetes to see if it helps with prostate cancer |
| Research Areas | Targeted therapies, therapeutics |
| Disease | Cancer |
| Commercial Partnerships | |
| Institutions | QUT, PA Hospital |
About the Project
Patients with metastatic prostate cancer are usually treated with Androgen Deprivation Therapy (ADT). Although successful in short term, the cancer usually progresses in few years. It is thought that the side effects of ADT, such as obesity and high levels of insulin, contribute towards the treatment resistance. Metformin is the most commonly used diabetic medication in the world. It lowers insulin and help patients lose weight. The purpose of this study is to evaluate whether Metformin will help delay the treatment resistance.
Translational Research - Milestone T3
This project is currently undertaking clinical trials.
> For information about commercial partnerships for this project, please contact QUT's commercial partner, BlueBox.
Professor Colleen Nelson
